Opthea Reports Positive Outcomes in Phase 2a Diabetic Macular Edema Trial

  • Jun 10, 2020 AEST
  • Team Kalkine

A developer of novel biologic for eye diseases, Opthea Limited (ASX:OPT) disclosed positive topline findings of its Phase 2a trial evaluating efficacy and safety of OPT-302 administered with aflibercept (Eylea®) for treatment of persistent diabetic macula edema (DME).

This trial is a randomized, sham-controlled, double-masked, proof-of-concept clinical study conducted at 53 sites in Australia, the US, Latvia and Israel.


The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. All pictures are copyright to their respective owner(s). Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK